Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis
Stopped The DMC made the recommendation to not pursue further enrollment given the lack of feasibility for this post-marketing study as designed.
Conditions
Interventions
- DRUG: Obeticholic Acid (OCA)
- DRUG: Placebo
Sponsor
Intercept Pharmaceuticals